ViaCyte to Present at JDRF TypeOneNation Summit Meetings in Washington DC and Los Angeles
SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.
Details of the presentations are as follows:
Event: 2016 JDRF TypeOneNation DC Summit
Speaker: Dr. Paul Laikind, President and CEO
Date/Time: March 5, 1:55 p.m. ET
Location: Bethesda North Marriott Hotel & Conference Center
Event: JDRF TypeOneNation Summit, Los Angeles
Panel: Technology and Research
Speaker: Dr. Eugene Brandon, Director, Strategic Relations & Project Management
Date/Time: March 13, 1:30 p.m. to 3:00 p.m. PT
Location: Pasadena Convention Center
ViaCyte’s VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes. More info on the clinical trial is here: https://clinicaltrials.gov/ct2/show/NCT02239354.
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goal of reducing the risk of hypoglycemia and diabetes-related complications without requiring long-term immune suppression.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.